India, Aug. 24 -- The following biotech stocks reached a 52-week high on August 21, 2026, as new trials continued enrolment and companies released positive clinical research data.
Eloxx Pharmaceuticals Inc. (ELOX)
Eloxx is a clinical-stage biopharmaceutical company focused on the production of small molecule drugs that target the ribosome to inhibit the translation of nonsense mutations and promote the production of functional proteins. Shares surged over 16% to reach a 52-week high of $23.40 on Monday.
For the second quarter of 2026, the company reported a net loss of $4.5 million, considerably higher than the $1.9 million from last year, as R&D expenses increased by over 200%.
Drug candidates currently in the pipeline include ZKN-013 ...